The Globe and Mail reports in its Friday edition that TD Cowen analyst Tim James continues to rank Andlauer Healthcare Group "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. James boosted his share target by a loonie to $54. Analysts on average target the shares at $47.50. Mr. James says in a note: "Andlauer delivered mixed Q3 results. Relatively weaker trends continued in consumer health products and U.S. truckload business, although we are encouraged to see a slight sequential improvement in U.S. EBITDA trends. Going forward, management appears more constructive on consumer health products and U.S. operations, while expecting continued organic growth in other areas, aided by ongoing investments in Canada. The company also continues to evaluate M&A opportunities selectively (focus on accretive, smaller deals) that offer strategic fit, supported by its solid balance sheet (0.7 times leverage ratio) and continued healthy FCF generation (mid-single digit yield). We have slightly improved our revenue and margin forecasts, which drives our target up."